1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CFF7B8BC4391D44D85257F41006F030D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-finding-showcasing-digital-impact-performance-measurement-assessing-digital-competitiveness?opendocument
18
19opendocument
20100.24.115.253
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Marketing Management » Digital Marketing

Finding & Showcasing Digital Impact: Performance Measurement and Assessing Digital Competitiveness

ID: 5400


Features:

5 Info Graphics

18 Data Graphics

400+ Metrics


Pages/Slides: 31


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Finding & Showcasing Digital Impact: Performance Measurement and Assessing Digital Competitiveness"

STUDY OVERVIEW

As digital marketing strategies and tactics evolve, digital marketing teams must stay focused on the customer to ensure they are effectively engaging with key customer groups. Today, more than ever, tracking the performance of various digital channels and key activities is crucial. While multichannel performance tracking is challenging, it offers huge competitive advantages for savvy companies.

This research identifies proven strategies and tactics used by high-performing organizations to effectively engage key customer groups through Digital and Multi-Channel marketing. This study also distills insights on how innovative Digital teams measure the impact of multichannel marketing and assess competitive advantages and vulnerabilities.

This study provides segment perspectives on large, mid and small companies as well as global vs. U.S.-only companies.


KEY TOPICS

  • Study Overview
  • Key Findings & Trends
  • Performance Measurement
  • Assessing Digital Competitiveness

SAMPLE KEY METRICS
  • Assessing the value of multichannel metrics
  • Valuable multichannel metrics across multiple marketing channels
  • Top 3 most effective performance metrics for key activities
  • Top 3 most effective performance metrics by channel
  • Factors undermining competitive digital deployment
  • Impact of regulation on digital approaches
  • Effective tactics for gaining approvals
  • Average timeline for content approval

SAMPLE KEY FINDINGS
  • Opportunity for Many Firms to Better Exploit Multichannel Attribution: Faced with a wealth of data in every channel, it is tempting to measure only what is readily available – and drive tactics to improve only what is measurable.  There remains a large gap between basic volume (traffic, clicks) and conversion measurements (downloads, signups), and more advanced analytics which uncover the interplay between channels.  DM teams which continually probe usage across channels will be better positioned to engage customers  and expand into new markets as competition becomes ever more fierce.

METHODOLOGY

Best Practices, LLC engaged 39 digital marketing leaders from 30 leading pharmaceutical, biotech, and life sciences companies. Thirteen study participants represent large pharma organizations, while the remaining benchmark class represent medium or small companies.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Manufacturing; Consumer Products; Diagnostic; Health Care; Marketing; Biopharmaceutical; Clinical Research; Laboratories; Chemical


Companies Profiled:
Novartis; Bristol-Myers Squibb; Roche; Astellas; Bayer; Teva Pharmaceutical Industries Ltd; Mylan; Ipsen; Alcon; Abbott; Eisai; Triplefin; Sanofi; cipla; Merck; Ferring Pharmaceuticals; Boehringer Ingelheim; Biogen; UCB Pharma; Hospira; Johnson & Johnson; GlaxoSmithKline ; Baxter Healthcare; Olympus Corporation; Sun Pharmaceutical; AstraZeneca; Abbvie; Genentech; Clarus Therapeutics; Zydus

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.